Mitochondria are the main energy-producing organelles of the cell. Five complexes embedded in the mitochondrial inner membrane, together constituting the oxidative phosphorylation (OXPHOS) system, comprise the final steps in cellular energy production. Many patients with a mitochondrial defect suffer from a so-called combined deficiency, meaning that the enzymatic activities of two or more complexes of the OXPHOS system are decreased. Numerous mutations have been described in nuclear genes that are involved in the functioning of a single complex of the OXPHOS system. However, little attention has been paid to patients with a deficiency of more than one complex of this particular system. In this study we have investigated four nuclear genes (OXA1L, MRS2L, YME1L and MIPEP) that might be involved in the pathology of combined enzymatic deficiencies of the OXPHOS system. Based on the results of yeast knockouts of these four proteins, we have sequenced the open reading frame of OXA1L in eight patients with an enzymatic deficiency of complexes I and IV. MRS2L, YME1L and MIPEP have been sequenced in three patients with a combined defect of complexes III and IV. No mutations were detected in these patients, showing that at least in these patients the OXPHOS system deficiency cannot be explained by a mutation in these four genes.
system complexes, except for complex II which is composed only of nuclear-encoded proteins.
Deficiencies in the enzyme activity of the OXPHOS system complexes can be classified as single or combined enzyme defects. The defects in both groups of patients can be of nuclear as well as mitochondrial origin. Much molecular genetic research has been performed in patients having an enzymatic deficiency of one enzyme complex. This has led to the identification of mutations in nuclear as well as mitochondrial genes encoding structural subunits of the complexes. In addition, mutations have also been described in nuclear genes necessary for the biogenesis of the OXPHOS system complexes (Antonicka et al 2003; Borisov 2002; Mootha et al 2003; Yano 2002) . Patients with an OXPHOS system deficiency present with a wide range of clinical symptoms. The most frequently encountered clinical phenotype is Leigh syndrome (Leigh 1951; Rahman et al 1996) .
Mitochondrial(mt) DNA mutations are a common cause of combined deficiencies of the OXPHOS system (DiMauro and Andreu 2000) . Many mutations in the mtDNA are located in genes required for mitochondrial translation (tRNAs and rRNAs). Mutations in these genes affect all 13 mitochondrial-encoded polypeptides (DiMauro and Andreu 2000; Sue and Schon 2001) . The most commonly encountered mutations in the translation genes are found in the tRNA Leu(UUR) gene and tRNA Lys causing MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes) and MERRF (myoclonic epilepsy with ragged-red fibres), respectively. However, so far only limited information is available about nuclear genes exerting an effect on more than one enzyme of the OXPHOS system in humans. Only one study has been published in which the authors searched for a disease-causing gene in a patient with a general mitochondrial defect (Seyda et al 2001) . The enzyme activites of the pyruvate dehydrogenase complex, the 2-oxoglutarate dehydrogenase complex, NADHcytochrome-c reductase, succinate dehydrogenase and succinate-cytochrome-c reductase were severely deficient. This study has led to the assignment of a region on chromosome 2 where the disease-causing gene should be located. Recently, we described a mutation in the GTP-binding domain of a mitochondrial elongation factor G1 leading to a combined OXPHOS deficiency and early fatal hepatoencephalophathy (Coenen et al 2004) .
In lower species such as yeasts, much more is known about proteins necessary for the function of more than one OXPHOS system complex. For many nuclear-encoded mitochondrial proteins it has been shown that mutations in the genes in yeast can result in a severe deficiency of the OXPHOS system (McEwen et al 1986) . We selected four genes: oxidase (cytochrome c) assembly 1-like (OXA1L), MRS2-like magnesium homeostasis factor (MRS2L), YME1-like (YME1L) and mitochondrial intermediate peptidase (MIPEP), all of which have been associated with a combined deficiency in lower species (Isaya et al 1992; Nargang et al 2002; Shah et al 2000; Zsurka et al 2001) . Studies in Saccharomyces cerevisiae have shown that an OXA1 defect leads to a defect in the insertion and processing of cytochrome-c oxidase subunit 2 (COII) in the mitochondrial membrane (He and Fox 1997; Hell et al 1997) . OXA1 depletion in Neurospora crassa results in reduced protein levels of OXPHOS system complexes I and IV (Nargang et al 2002) . MRS2L is involved in magnesium homeostasis. Mrs2 disruptants show defects in group II intron splicing and reduced levels of cytochrome complexes (CIII and CIV). YME1L, present in the mitochondrial intermembrane space, and a member of the triple A metalloprotease family, is involved in the turnover of unassembled COII (Nakai et al 1995; Pearce and Sherman 1995; Weber et al 1996) . Additional studies in yeast have demonstrated that inactive YME1 has a general effect on mitochondria as it influences the morphology of the mitochondria and the growth of the yeast. MIPEP is involved in the processing of nuclear-encoded subunits of the OX-PHOS system (Isaya et al 1992 (Isaya et al , 1994 . The protein cleaves octapeptides from the precursor subunits of the OXPHOS system, resulting in mature subunits. Disruption of this gene in yeast leads to a severe defect in complex III and IV of the OXPHOS system (Isaya et al 1994) .
For these four candidate genes we have performed sequence analysis in patients with a combined enzymatic deficiency of the OXPHOS system in order to determine whether a mutation in these genes can explain the mitochondrial disorder.
MATERIALS AND METHODS
Cell culture and biochemical measurements: Human skin fibroblasts were cultured until confluency in medium 199 supplemented with 10% fetal calf serum, bicarbonate and antibiotics.
The activities of the mitochondrial respiratory chain complexes were measured in skin fibroblasts. The method was slightly modified from that used for muscle tissue (Bentlage et al 1996) .
Patients:
We selected 3 patients with a combined complexes III and IV deficiency and 8 patients with a combined complexes I and IV deficiency (Table 1) . In these patients the OXPHOS system defect was at least present in cultured skin fibroblasts. The mtDNA of the patients was analysed for the commonly occurring 3243 MELAS, 8344 MERFF and 8993 Leigh/NARP mutations as well as large deletions. Sequence analysis: Total RNA was isolated from patients' fibroblasts with the use of RNAzol (Campro Scientific); cDNA was prepared using reverse transcriptase (Invitrogen). Sequence analysis of the open reading frame was performed in the four genes OXA1L, YME1L, MIPEP and MRS2L. The sequence of the oligonucleotide primers used for the amplification of the cDNA can be obtained from the author. The cDNA was amplified in 20 mmol/L Tris-HC1 and 50 mmol/L KC1 with 25 ng forward and reverse primers, 2.5 mmol/L dNTPs, 1-2 mmol/L MgCl 2 and 1 unit Taq polymerase (Invitrogen) in a total volume of 25 μl. Both strands were used for direct sequencing (ABI Prism, model 377 version 2.1.2), using the ABI Prism TaqDyeDeoxy terminator cycle sequencing ready kit (Applied Biosystems).
RESULTS
As studies in Neurospora crassa show that disruption of OXA1 affects complexes I and IV, we sequenced OXA1L (Genbank accession no. X80695) in 8 patients with a defect in these two enzyme complexes. No mutations could be detected in this gene, although two polymorphisms T311C and INS1435AGC (base-numbers according to AJ001981) have been detected. BLAST searches show that both polymorphisms are present in available human expressed sequence tags. The other three genes have been sequenced in patients with a combined deficiency of complexes III and IV. This did not lead to the detection of any mutation in these genes. One polymorphism was detected in MRS2L at nucleotide position 966 (Genbank accession no. XM 011365) where an A was substituted by a G. This substitution did not lead to a change of the amino acid, glutamine. Database searches showed that the polymorphism was present in dbSNP (rs2793422). Two variants were detected in MIPEP. One polymorphism, present in patient as well as control material, at nucleotide position 1019 (CGA > CAA) did not affect the amino acid, arginine. The other variant was present at position 671 (AAT > AGT), leading to the substitution of asparagine by serine. One patient was heterozygous for this variation; the base substitution was not present in control material or expressed sequence tags (ESTs) suggesting that the variation is a polymorphism. No variations were detected in YME1L.
DISCUSSION
Four genes were selected that are known to play a role in combined deficiencies of the OXPHOS system in lower species. Sequence analysis was performed in the human orthologues of these four genes in patients with combined deficiencies of complexes I and IV or complexes III and IV.
Following the initial publication of the OXA1L cDNA (Genbank accession no. X80695), the sequence has been revised after the detection of two additional in-frame start codons at the 5 site of OXA1L (Genbank accession no. AJ001981) (Bonnefoy et al 1994; Rotig et al 1997) . We were unable to amplify this OXA1L cDNA sequence (Rotig et al 1997) . The fragment that did amplify from fibroblast mRNA corresponds to the first published OXA1L sequence with Genbank accession no. X80695 (Bonnefoy et al 1994) . This is also the fragment that is retrieved when BLAST searches are performed with the OXA1 sequence in ESTs and protein databases. We therefore propose that the OXA1L cDNA sequence described by Bonnefoy and co-workers is probably the cDNA expressed in fibroblasts (Bonnefoy et al 1994) . As both complexes I and IV are affected in N. crassa, we sequenced the OXA1L open reading frame in 8 patients with a combined complexes I and IV deficiency. No mutations have been detected in these patients. However, we did detect two polymorphisms. BLAST searches show that the variations also occur in ESTs.
Beside sequence analysis of OXA1L we also sequenced the open reading frame of three other genes (MRS2L, YME1L, MIPEP) . Disruption of these genes in lower species mainly affects complexes III and IV. We therefore sequenced these genes in patients with a combined deficiency of complexes III and IV. No mutations could be detected in these three genes. Disruption of MRS2 in yeast leads to a severe defect in the mitochondrial magnesium concentrations. It has been demonstrated that Mrs2p is a constituent of the Mg 2+ influx system, probably forming a homo-oligomeric Mg 2+ channel (Kolisek et al 2003) . In bacteria it has been demonstrated that CorA can also form such complexes (Smith and Maguire 1998) . Related homologues of Mrs2p such as CorA are present in the bacterial plasma membrane. Overexpression of CorA or human Mrs2 in yeast can partially suppress the petite phenotype of a mrs2 disruption mutant (Bui et al 1999; Zsurka et al 2001) . Mutations in this gene lead to severe growth deficiency of Salmonella typhimurium.
In yeast the function of YME1 has been mainly studied in the relation to complex IV as it is implicated in the turnover of unassembled COII (Nakai et al 1995; Pearce and Sherman 1995; Weber et al 1996) . Human YME1L can functionally complement a yeast yme1 disruptant. This indicates that YME1L is the functional orthologue of yeast YME1 (Shah et al 2000) . In N. crassa a protein called IAP-1 (intermembrane space AAA protease) has been identified with 45.9% sequence identity to Yme1 of S. cerevisiae (Klanner et al 2001) . In contrast to yeast, no defect in mitochondrial morphology was observed in a N. crassa mutant lacking IAP-1. However when expressed in yme 1-disrupted yeast cells, IAP-1 could substitute for the function of YME1 in maintaining the mitochondrial morphology.
The last gene that was investigated in the patients with a defect of complex III and IV is MIPEP. The MIPEP open reading frame encodes a 713-amino-acid protein that is 92% similar to rat MIP and 54% similar to yeast MIP (Chew et al 1997) . MIP proteins from Schizophyllum commune and rat can complement the loss of mitochondrial function caused by inactivation of YMIP in yeast (Isaya et al 1995) . This study demonstrates the conserved function of the protein in diverse species.
Although the protein products of OXA1L, MRS2L, YME1L and MIPEP clearly have a role in the functioning of more than one complex of the OXPHOS system in lower species, none of the patients harboured a mutation in the human homologues of these genes. This implies that other genes involved in the functioning of the OXPHOS system must be mutated in these patients. The large number of genes involved in the whole process of OXPHOS system formation makes it difficult to predict which genes might be mutated in the diverse patients. To identify all the genes involved in mitochondrial disorders, more robust techniques will be needed, as it is impossible to sequence all candidate genes in every patient. Microcellmediated chromosome transfer can be used to search for genes in patients with an OXPHOS system deficiency (Coenen et al 2004; Zhu et al 1998) . The disadvantage is that this method is very time consuming. New techniques, such as proteomics and microarrays, may provide initial clues as to which genes might be mutated in OXPHOS deficiency patients. This will hopefully lead to more rapid identification of the disease-causing genes in patients with a combined deficiency of the OXPHOS system.
